In April 2025, our partner Jazz announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of ...

Two biosimilars developed under the Teva - Alvotech partnership have been granted FDA approval with interchangeability, including SELARSDI. In February 2024, the FDA approved SIMLANDI® ...

The U.S. FDA has approved SELARSDI (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April ...

In this interview, rare disease expert Oxana Iliach discusses challenges with rare disease drug development and how they can ...

A new straightforward way to make an injectable gel capable of releasing multiple drugs at specific speeds improves ...

While significant progress has been made in developing treatments for rare diseases—highlighted by the approval of over 800 drugs for orphan diseases since ...

“The breadth of data shared at AACR highlights the strength of our oncology portfolio across antibody-drug ... clinical development of its product candidates and enrollment in its clinical trials; ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment landscape for head and neck and lung cancer, and implications for specific drug ...

China’s pharmaceutical industry is witnessing a seismic shift as it transitions from prioritising generic drug production ... amount in innovation. The development of a new medicine is complex ...

Pharmaceutical companies in Europe are requesting the EU to adopt drug pricing strategies comparable to the ... and Novartis announced $23bn on manufacturing and research and development (R&D).

These changes can have a direct effect on drug safety and even drug costs. The proposed changes would include using AI based computational models instead of animal testing, which falls under what ...